Neumora Therapeutics operates as a clinical-stage biotechnology company.
Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 11, 2022 | Series B | $112M | 10 |
![]() |
— | Detail |
Oct 7, 2021 | Series A | $400M | 14 |
![]() |
— | Detail |
Oct 7, 2021 | Corporate Round | $100M | 1 |
![]() |
— | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |